StockTipsArenaBeta

BUY Aurobindo Pharma — Ashish Kyal, Waves Strategy Advisors

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byAshish Kyal, Waves Strategy AdvisorsHorizon: NA (inferred 1–3 months)29 Jul 2026via CNBC Awaaz.

Entry₹1,556.7Inferred
Target₹1,680
Total upside +7.92% (call closed)
Stop loss₹1,545-0.75% risk
Exit₹1,5453 Aug 2026, 12:08 pm
Stop-loss hit-0.75%
Follow Ashish Kyal for new calls(20% target hit, 10 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 39 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 3 Aug 2026
5 supporting3 neutral2 opposing
Supports the BUY call (5)

3 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·29 Jul · 4d ago

Aurobindo Pharma has signed a non-exclusive voluntary license agreement with MSD to supply generic alimatravir to 129 Low- & Middle-Income Countries (LMICs). This royalty-free agreement aims to expand

BSE · Company Update·24 Jul · 1w ago

(opens in new tab)

Aurobindo Pharma is acquiring majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA, expanding its business.

BSE · Company Update·23 Jul · 1w ago

(opens in new tab)

Aurobindo Pharma subsidiary gets Brazil regulator nod for Hyderabad biosimilars facility

NewsCnbc-Tv18·21 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (3)

Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries

NewsCnbc-Tv18·24 Jul · 1w ago

(opens in new tab)

Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million

NewsCnbc-Tv18·23 Jul · 1w ago

(opens in new tab)

Aurobindo Pharma Limited has incorporated a new wholly owned stepdown subsidiary in Indonesia.

NSE · Acquisition·10 Jul · 3w ago

(opens in new tab)
Weighs against the BUY call (2)

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

NewsHbl·22 Jul · 2w ago

(opens in new tab)

Pharma stocks decline; Aurobindo Pharma down over 4%

NewsHbl·22 Jul · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Ashish Kyal, Waves Strategy Advisors

Every call and its outcome